DaShenLin Pharmaceutical Group Co., Ltd.

SHSE:603233 Stock Report

Market Cap: CN¥17.4b

DaShenLin Pharmaceutical Group Future Growth

Future criteria checks 3/6

DaShenLin Pharmaceutical Group is forecast to grow earnings and revenue by 24.9% and 16.7% per annum respectively. EPS is expected to grow by 25.1% per annum. Return on equity is forecast to be 17.5% in 3 years.

Key information

24.9%

Earnings growth rate

25.1%

EPS growth rate

Consumer Retailing earnings growth41.6%
Revenue growth rate16.7%
Future return on equity17.5%
Analyst coverage

Good

Last updated19 Nov 2024

Recent future growth updates

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

Sep 30
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Aug 20
DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Jun 17
Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Jun 09
Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

May 21
Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Apr 09
Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Mar 17
Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Earnings and Revenue Growth Forecasts

SHSE:603233 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202638,4491,6762,3423,97012
12/31/202532,7301,4142,0533,54612
12/31/202426,9491,0712,7173,2767
9/30/202426,5398501,4883,202N/A
6/30/202425,8859071,6343,464N/A
3/31/202425,3361,0682,0493,648N/A
12/31/202324,5311,1661,3773,174N/A
9/30/202324,1541,2872,0554,160N/A
6/30/202323,5191,2391,8463,815N/A
3/31/202322,5181,1482,5293,843N/A
12/31/202221,2481,0362,7223,757N/A
9/30/202219,2228961,2602,411N/A
6/30/202218,4258601,0272,237N/A
3/31/202217,3778353841,708N/A
12/31/202116,7597912601,555N/A
9/30/202116,4461,0136821,833N/A
6/30/202115,6971,1131,0972,066N/A
3/31/202115,2801,1221,2862,145N/A
12/31/202014,5831,0621,1621,954N/A
9/30/202013,5931,0141,4301,966N/A
6/30/202012,8299171,2291,759N/A
3/31/202011,9257991,2251,779N/A
12/31/201911,1417031,2061,708N/A
9/30/201910,6016741,1721,462N/A
6/30/201910,0296248521,285N/A
3/31/20199,4045696131,119N/A
12/31/20188,859532319874N/A
9/30/20188,421522-118663N/A
6/30/20188,003515N/A553N/A
3/31/20187,718505N/A511N/A
12/31/20177,421475N/A648N/A
9/30/20176,992462N/A545N/A
6/30/20176,824458N/A497N/A
3/31/20176,545433N/A502N/A
12/31/20166,274430N/A496N/A
6/30/20165,681427N/A406N/A
3/31/20165,464415N/A445N/A
12/31/20155,265395N/A469N/A
12/31/20144,545266N/A449N/A
12/31/20133,707197N/A288N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603233's forecast earnings growth (24.9% per year) is above the savings rate (2.8%).

Earnings vs Market: 603233's earnings (24.9% per year) are forecast to grow slower than the CN market (26.1% per year).

High Growth Earnings: 603233's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 603233's revenue (16.7% per year) is forecast to grow faster than the CN market (13.8% per year).

High Growth Revenue: 603233's revenue (16.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 603233's Return on Equity is forecast to be low in 3 years time (17.5%).


Discover growth companies